Stratification of enterochromaffin cells by single-cell expression analysis
Dynamic interactions between gut mucosal cells and the external environment are essential to maintain gut homeostasis. Enterochromaffin (EC) cells transduce both chemical and mechanical signals and produce 5-hydroxytryptamine to mediate disparate physiological responses. However, the molecular and cellular basis for functional diversity of ECs remains to be adequately defined. Here, we integrated single-cell transcriptomics with spatial image analysis to identify 14 EC clusters that are topographically organized along the gut. Subtypes predicted to be sensitive to the chemical environment and mechanical forces were identified that express distinct transcription factors and hormones. A Piezo2 + population in the distal colon was endowed with a distinctive neuronal signature. Using a combination of genetic, chemogenetic, and pharmacological approaches, we demonstrated Piezo2 + ECs are required for normal colon motility. Our study constructs a molecular map for ECs and offers a framework for deconvoluting EC cells with pleiotropic functions.
Authors
- Brandon Y. Liu
- Ada Koo (ORCID: https://orcid.org/0000-0003-2414-0852)
- Mark Perelis (ORCID: https://orcid.org/0000-0001-5435-2552)
- Jill Wykosky
- Shanti Diwakarla (ORCID: https://orcid.org/0000-0003-2328-3528)
- Kari Lee
- Jie Huang (ORCID: https://orcid.org/0000-0001-7951-2217)
- John B. Furness (ORCID: https://orcid.org/0000-0002-0219-3438)
- Linda J. Fothergill (ORCID: https://orcid.org/0000-0002-4022-1807)
- G Yeo
- Yan Song (ORCID: https://orcid.org/0000-0001-8423-846X)
- Brid Callaghan
Institutions
- The University of Melbourne (AU)
- Florey Institute of Neuroscience and Mental Health (AU)
- University of California San Diego (US)
- Takeda (Japan) (JP)
Publication Details
- Journal
- eLife
- Published
- 2025-04-04
- DOI
- https://doi.org/10.7554/elife.90596.3
- Citations
- 2
- Primary Topic
- Gastrointestinal disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Takeda Pharmaceuticals U.S.A.
- National Institutes of Health